dbACP: A Comprehensive Database of Anti-Cancer Peptides

30 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp02160 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :10.6 ± 0.4 µM
dbacp02161 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :13.0 ± 1.0 µM
dbacp02162 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :12.1 ± 1.6 µM
dbacp02163 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :37 ± 4.3 µM
dbacp02168 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02169 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02170 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02171 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02172 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02173 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >40% at 12.5μM approx.
dbacp02174 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02175 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02176 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >45% at 12.5μM approx.
dbacp02177 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02178 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02179 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02180 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02209 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02210 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02211 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02212 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02213 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02214 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02215 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >75% at 12.5μM approx.
dbacp02216 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02217 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >85% at 12.5μM approx.
dbacp02218 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02219 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02220 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >85% at 12.5μM approx.
dbacp02221 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >70% at 12.5μM approx.